Experimental and clinical evidence links reduced SOCS1 activity to the development of autoimmune conditions such as RA, SLE, vasculitis, and Sjögren’s syndrome, underscoring its key regulatory role (39–41). Here, SOCS1 is linked to systemic lupus erythematosus.